Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xilio Therapeutics (XLO) Gains from Sales and Divestitures (2024 - 2025)

Historic Gains from Sales and Divestitures for Xilio Therapeutics (XLO) over the last 2 years, with Q3 2025 value amounting to $111375.0.

  • Xilio Therapeutics' Gains from Sales and Divestitures rose 188282.0% to $111375.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $111375.0, marking a year-over-year increase of 188282.0%. This contributed to the annual value of $5617.0 for FY2024, which is N/A changed from last year.
  • As of Q3 2025, Xilio Therapeutics' Gains from Sales and Divestitures stood at $111375.0, which was up 188282.0% from $111375.0 recorded in Q2 2025.
  • Xilio Therapeutics' Gains from Sales and Divestitures' 5-year high stood at $111375.0 during Q1 2025, with a 5-year trough of $4777.0 in Q1 2024.